Connect your AI

Immunome IMNM Gain (loss) on available-for-sale debt securities

Gain (loss) on available-for-sale debt securities at other companies

Flywire CorporationFLYW

-$34K+73.6%

Vera TherapeuticsVERA

-$942K-461%

ImmunomeIMNM

$0+100%

Grand Canyon EducationLOPE

-$696K-9,843%

First Financial BanksharesFFIN

$0—

ZymeworksZYME

$95K-62.5%

Other financials

Income statement

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's gain (loss) on available-for-sale debt securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Immunome's gain (loss) on available-for-sale debt securities?: Immunome (IMNM) reported gain (loss) on available-for-sale debt securities of -$0 in Q1 2026.
What does gain (loss) on available-for-sale debt securities mean?: This represents the change in the fair value of debt securities held in the investment portfolio that have not yet been sold. It captures market-driven fluctuations in the value of liquid assets held by the company. Monitoring this metric provides insight into the volatility and risk profile of the company's treasury investment strategy.